A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + Tak-700 With Androgen Deprivation Therapy + Bicalutamide In Patients With Newly
Posted Date: May 15, 2019
- Investigator: Timothy Struve
- Specialties: Cancer, Oncology, Prostate Cancer
- Type of Study: Drug
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide. Efficacy will be determined by overall survival. There are 2 arms in this study. The first arm has the drug TAK-700 and patients will receive 300 mg, PO, twice daily. The second arm has the drug bicalutamide and patients will receive 50 mg, PO, q daily.
Criteria:
Clinical Diagnosis Of Metastatic Prostate Cancer. Serum Testosterone Within Institutional Limits Of Normal. Psa = 2 Ng/Ml Within 90 Days Prior To Initiation Of Androgen Deprivation. Therapy (For Early Induction) Or Prior To Registration (For Late Inductio
Keywords:
Cancer, Prostate, Metastatic Hormone, Newly Diagnosed, S1216
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com